Driving progress in biopharma and medical technology through innovation, investment, and strategic alliances.
A French chemist and microbiologist, whose foundational contributions to germ theory, vaccination, and pasteurization revolutionized medical science
In Singapore, GenBio will engage with key players in the pharmaceutical and biotech sectors to discuss its scientific platform and potential strategic avenues.
In the domain of discovery, luck favors only the mind that is ready.”— Louis Pasteur
ALISO VIEJO, CA, UNITED STATES, August 1, 2026 /EINPresswire.com/ — GenBio Inc., a privately owned biotechnology firm focused on creating therapeutic and wellness products from rare,
scientifically validated natural bioactive compounds, has announced its participation in the
2026 Asia Bio Partnering Forum, scheduled for September 1–2 at Marina Bay Sands in Singapore.
Representatives from GenBio’s leadership will be accessible via the partneringONE® system for private
discussions with pharmaceutical and biotech leaders, corporate development groups, and other
qualified strategic entities.
The organization is advancing a multidisciplinary scientific approach dedicated to discovering, purifying, and
formulating bioactive compounds from natural sources, which hold promise for addressing
antimicrobial resistance, inflammation, and other human health challenges.
GenBio’s development pipeline includes:
• An efflux pump inhibitor initiative examining the capacity to counter bacterial resistance pathways
and boost the efficacy of antimicrobials;
• An antibacterial discovery and drug-repurposing effort carried out in partnership with Hypha
Discovery in the United Kingdom;
• An anti-inflammatory development program backed by ongoing research activities in Australia; and
• Complementary health and wellness products stemming from the company’s extensive bioactive
compound platform.
“Taking part in the Asia Bio Partnering Forum gives GenBio a valuable chance to connect directly with
international decision-makers from the pharmaceutical and biotechnology industries,” said Giles Tilley,
Chief Executive Officer of GenBio Inc. “The Asia-Pacific region is becoming a pivotal hub for global life-sciences
innovation, and Singapore offers an excellent venue for meaningful conversations about GenBio’s
research platform, development initiatives, and long-term strategic possibilities.”
GenBio is currently organizing controlled discussions regarding strategic opportunities tied to the company
and its scientific assets. Following management review and the signing of appropriate confidentiality
agreements, qualified parties will gain access to progressively shared due diligence materials.
“Partnering systems can become extremely competitive in a short timeframe,” said Todd D. Sonoga, Director and Chief
Marketing Officer of GenBio Inc. “By introducing GenBio ahead of the meeting scheduling phase, we hope
to give prospective strategic partners enough time to grasp our scientific platform, examine our
company profile, and submit a request to meet with management.”
The Asia Bio Partnering Forum convenes biotechnology and pharmaceutical executives, corporate
development professionals, institutional investors, and emerging life-sciences firms from throughout the
Asia-Pacific region and global markets. The partneringONE platform facilitates one-on-one meetings.
Qualified organizations wishing to connect with GenBio can find the company on partneringONE once
the platform goes live on August 4, 2026.
About GenBio Inc.
GenBio Inc. is a U.S.-headquartered biotechnology company dedicated to creating next-generation antimicrobial, anti-inflammatory, and complementary health products sourced from rare natural bioactive compounds.
In collaboration with research partners in Australia and the United Kingdom, GenBio employs systematic compound identification, biological screening, and development studies to convert naturally occurring bioactivity into commercially viable therapeutic and health solutions.
Crafted by Nature. Discovered, Purified, and Formulated by GenBio
